Regulatory approval

Published by the Health Canada. Approved

MEKINIST (trametinib) is indicated, as a monotherapy or in combination with dabrafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

This is written in the approval document.

Citation

Novartis Pharmaceuticals Canada Inc. Mekinist (trametinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083524.PDF. Revised February 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	BRAF p.V600E	Melanoma	Trametinib
HC (1)	BRAF p.V600K	Melanoma	Trametinib
HC (1)	BRAF p.V600E	High-Grade Glioma, NOS	Dabrafenib, Trametinib